Evidence syntheses — page 7
140 structured review questions, each with a registered PICO frame, a reproduced search, an included-studies table, a summary of findings and an amendment log.
Reviews
-
In the population defined for hypoactive sexual desire and erectile dysfunction, what is the effect of PT-141 (bremelanotide) compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate04 Feb 2026 -
In the population defined for hypoactive sexual desire and erectile dysfunction, what is the incidence of adverse events leading to discontinuation with PT-141 (bremelanotide) compared with its comparator?
Moderate05 Jun 2026 -
In the population defined for type 2 diabetes mellitus, what is the effect of Retatrutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate10 May 2026 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its comparator?
Moderate12 Jun 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the anchor outcome for this…
High04 Jul 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
High14 Apr 2026 -
In the population defined for heart failure with preserved ejection fraction and obesity, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate14 Apr 2025 -
In the population defined for heart failure with preserved ejection fraction and obesity, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its comparator?
Moderate23 Jan 2026 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Semaglutide, oral compared with the comparator used in its contributing trials on the anchor outcome for this…
Moderate01 Nov 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to discontinuation with Semaglutide, oral compared with its comparator?
Moderate02 Mar 2026 -
In the population defined for cognitive performance and neuroprotection, what is the effect of Semax compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Very low26 Dec 2024 -
In the population defined for cognitive performance and neuroprotection, what is the incidence of adverse events leading to discontinuation with Semax compared with its comparator?
Very low11 Jan 2025 -
In the population defined for primary mitochondrial myopathy and bioenergetic disorders, what is the effect of SS-31 (elamipretide) compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate11 Nov 2025 -
In the population defined for primary mitochondrial myopathy and bioenergetic disorders, what is the incidence of adverse events leading to discontinuation with SS-31 (elamipretide) compared with its comparator?
Moderate14 May 2025 -
In the population defined for hiv-associated lipodystrophy and excess visceral adiposity, what is the effect of Tesamorelin compared with the comparator used in its contributing trials on the anchor outcome for this indication?
Moderate19 Nov 2025 -
In the population defined for hiv-associated lipodystrophy and excess visceral adiposity, what is the incidence of adverse events leading to discontinuation with Tesamorelin compared with its comparator?
Moderate08 Dec 2024 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor outcome for this…
Moderate13 Nov 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
Moderate22 May 2026 -
In the population defined for obstructive sleep apnoea with obesity, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the anchor outcome for this indication?
High27 Sep 2025 -
In the population defined for obstructive sleep apnoea with obesity, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
High27 Jun 2025
page 7 of 7